

www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

HMGB1 Rabbit pAb

Catalog Number: bs-0664R
Target Protein: HMGB1

Concentration: 1mg/ml

Form: Liquid Host: Rabbit

Clonality: Polyclonal

Isotype: IgG

Applications: Flow-Cyt (1µg/Test)

Reactivity: Human, Mouse, Rat (predicted:Cow)

Predicted MW: 25 kDa Entrez Gene: 3146 Swiss Prot: P09429

Source: KLH conjugated synthetic peptide derived from human HMGB1: 75-170/215.

Purification: affinity purified by Protein A

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.


Background: High Mobility Group Box-1 (HMGB1) is a cytokine implicated in the pathogenesis of


rheumatoid arthritis (RA) and other inflammatory diseases. The cholinergic anti-

inflammatory pathway, a vagus nerve dependent mechanism, inhibits HMGB1 release in

experimental disease models


VALIDATION IMAGES







Blank control (blue line): MCF7 (blue). Primary Antibody (green line): Rabbit Anti-HMGB1 antibody (bs-0664R) Dilution: $1\mu g/10^6$ cells; Isotype Control Antibody (orange line): Rabbit IgG . Secondary Antibody (white blue line): Goat anti-rabbit IgG-FITC Dilution: $1\mu g$ /test. Protocol The cells were fixed with 70% ethanol (Overnight at 4°C) and then permeabilized with 90% ice-cold methanol for 30 min on ice. Cells stained with Primary Antibody for 30 min at room temperature. The cells were then incubated in 1 X PBS/2%BSA/10% goat serum to block non-specific protein-protein interactions followed by the antibody for 15 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.

The figure annotation: The blue histogram is unstained cells. The Orange histogram is cells stained with Rabbit IgG/FITC (bs-0295P-FITC) The green histogram is cells stained with Rabbit Anti-HMGB1/FITC Conjugated antibody (bs-0664R-FITC). Controls Positive control: HepG 2 cells Isotype control: Cell lines treated with Rabbit IgG/FITC (bs-0295P-FITC). instead of the primary antibody to confirm that primary antibody binding is specific. $5\mu gin 100 \ \mu L 1 \ X \ PBS \ containing 0.5\% \ BSA.$







Positive control: HepG2 cells Concebtration: $5\mu g/10^6$ cells Incubation conditions: Avoid light, 30 minutes on the ice.

PRODUCT SPECIFIC PUBLICATIONS

[IF=17.694] Fu Shunli. et al. Temperature sensitive liposome based cancer nanomedicine enables tumour lymph node immune microenvironment remodelling. NAT COMMUN. 2023 Apr;14(1):1-17 IHC; MOUSE. 37076492

[IF=17.4] Anning Song. et al. Yeast Nanoparticle - powered Tumor Photodynamic - Immunotherapy. NANO TODAY. 2024 Feb;54:102109
IF; Mouse . 10.1016/j.nantod.2023.102109

[IF=15.621] Feng B et al. Enhancing Triple Negative Breast Cancer Immunotherapy by ICG - Templated Self - Assembly of Paclitaxel Nanoparticles. Advanced Functional Materials, 2019 1906605. FCM, ICC; MOUSE. doi:10.1002/adfm.201906605

[IF=15.881] Yuting Shen. et al. Tailoring Chemoimmunostimulant Bioscaffolds for Inhibiting Tumor Growth and Metastasis after Incomplete Microwave Ablation. Acs Nano. 2021;XXXX(XXX):XXX-XXX IF; Mouse . 34881574

[IF=15.153] Songlin Gong. et al. Tumor Microenvironment-Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade-Amplified Immune Response against Tumor Growth, Metastasis and Recurrence. SMALL. 2022 Nov;:2107061 IF; MOUSE. 36323618